Pharmaceuticals News and Research

RSS

Jazz Pharmaceutical receives USPTO patent for Xyrem oral solution

Jazz Pharmaceuticals, today announced that the United States Patent and Trademark Office has issued a patent related to Xyrem oral solution titled "Microbiologically Sound and Stable Solutions of Gamma-Hydroxybutyrate Salt for the Treatment of Narcolepsy."

22 Dec 2010

Mesa Labs announces acquisition of Apex's biological indicators business

Mesa Laboratories, Inc., a Lakewood, Colorado based manufacturer of electronic instruments and disposables today announced the acquisition of the biological indicators business of Apex Laboratories, Inc., a North Carolina based company. The acquisition of the Apex business is expected to be immediately accretive to Mesa's earnings per share.

22 Dec 2010

AIDS Healthcare Foundation sues AIDS drug maker for overcharging

AIDS Healthcare Foundation (AHF) will host a press teleconference on Wednesday, December 22nd at 9:30 AM Pacific/12:30 PM Eastern to announce that it has filed a lawsuit against Johnson & Johnson’s Tibotec Therapeutics for overcharging AHF for AIDS drugs purchased under the 340B program.

21 Dec 2010

Isis commences ISIS-APOCIIIRx Phase 1 trial in hypertriglyceridemia

Isis Pharmaceuticals, Inc. announced the initiation of a Phase 1 study of ISIS-APOCIIIRx, an antisense drug designed to lower triglycerides to treat a variety of diseases associated with elevated triglycerides. Hypertriglyceridemia, a condition characterized by elevated levels of triglycerides, is an independent risk factor for cardiovascular disease and is a component of numerous cardiovascular and metabolic diseases, including metabolic syndrome.

21 Dec 2010

Pro-Pharmaceuticals, Mount Sinai collaborate to evaluate anti-fibrotic effects of Galectin-targeting compounds

Pro-Pharmaceuticals, Inc., the leading developer of Galectin therapeutics to treat cancer and fibrosis, today announced it has entered into a new research collaboration with Mount Sinai School of Medicine to evaluate in pre-clinical models, the anti-fibrotic effects of several of the Company's novel, Galectin-targeting compounds.

21 Dec 2010

Study aims to deliver safer bone marrow transplant treatment strategy in patients with multiple myeloma cancer

A national clinical trial, which opens imminently, will aim to assess the impact of a novel anti-cancer drug in the setting of donor bone marrow transplantation for myeloma.

21 Dec 2010

Poniard completes voluntary prepayment of $12.35 million under senior secured loan facility

Poniard Pharmaceuticals, Inc., a biopharmaceutical company focused on innovative oncology therapies, announced today that it has completed the voluntary prepayment of the $12.35 million aggregate principal, interest and fees due under its senior secured loan facility with GE Business Financial Services Inc. and Silicon Valley Bank.

21 Dec 2010

BioInvent, Japanese pharmaceutical extends partnership for therapeutic candidate development

BioInvent International AB today announced that it has signed an agreement to extend its existing collaboration with an undisclosed Japanese pharmaceutical group.

21 Dec 2010

XFELs technology can track damaged membrane protein structure

Australian researchers have identified a way to measure the structure of membrane proteins despite being damaged when using X-ray Free-Electron Lasers, a discovery that will help fast track the development of targeted drugs using emerging XFELs technology.

21 Dec 2010

Laser restoration therapy promotes hair regrowth in women

Many Women suffering from hair loss are turning to Advanced Hair Studios and discovering advanced laser therapy as a method along with other procedures to overcome thinning hair.

21 Dec 2010

Amylin submits metreleptin rolling submission BLA for treatment of rare forms of lipodystrophy

Amylin Pharmaceuticals, Inc. today announced that it has submitted the initial sections of a rolling submission for a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for the use of metreleptin to treat diabetes and/or hypertriglyceridemia (high levels of triglycerides in the bloodstream) in patients with rare forms of lipodystrophy.

21 Dec 2010

Silence provides year-end update on trading and offer-period

Silence Therapeutics plc, a leading global biotechnology company dedicated to the discovery, development and delivery of targeted, systemic RNA interference (RNAi) therapeutics for the treatment of serious diseases, today provides a year-end update on trading and the offer-period.

21 Dec 2010

Auspex, Teva Pharmaceutical to develop deuterium-containing drug

Auspex Pharmaceuticals, announced today that it has signed a deal involving a promising deuterium-containing drug with Teva Pharmaceutical Industries.

21 Dec 2010

New research sheds light on complex regulatory pathways for effective innate immune system

New research by scientists at the University of California, San Diego School of Medicine and Skaggs School of Pharmacy and Pharmaceutical Sciences reveals that the immune system has an effective backup plan to protect the body from infection when the "master regulator" of the body's innate immune system fails.

21 Dec 2010

Study: Chemotherapy can improve survival rate in older adolescents with leukemia

Research led by St. Jude Children-s Research Hospital investigators will likely impact how acute lymphoblastic leukemia is treated in young adults and shows older adolescent age does not dictate worse outcomes against the most common childhood cancer.

21 Dec 2010

Veeva announces seamless integration of CRM solution with Mederi

Veeva Systems, the global leader in cloud CRM solutions for the life sciences industry announces the ability to integrate with Mederi, a leading provider of network intelligence and insights for the healthcare industry. The seamless integration between Veeva CRM and Mederi allows pharmaceutical companies to manage their customer relationships and to analyse professional networks within one application, ensuring a much more coordinated and effective interaction with key stakeholders.

20 Dec 2010

Brilinta – AstraZeneca’s new blood thinner faces FDA hurdle

AstraZeneca’s new blood thinner that was pitched against Plavix, the world’s second-best selling drug failed to live up to expectations making stocks drop to a two year low, the steepest decline since Nov. 21, 2008, and the worst performance today on the 18-company Bloomberg Europe Pharmaceutical Index.

20 Dec 2010

Opsens unveils EasyWire for growth market of Fractional Flow Reserve for coronary lesion assessment

Opsens Inc. today unveiled the EasyWire, developed by its medical division for the growth market of Fractional Flow Reserve for coronary lesion assessment.

20 Dec 2010

Rexahn granted Japanese patent for preclinical compound RX-0047

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced that it was awarded patent 4,546,454 entitled, "Antisense Oligonucleotides that Inhibit Expression of HIF-1," by the Japanese Patent Office.

20 Dec 2010

Idera reports positive data from IMO-2125/ribavirin combination Phase 1 trial in null-responder HCV patients

Idera Pharmaceuticals, Inc. announced today preliminary data from a 4-week dose-ranging Phase 1 clinical trial of IMO-2125 in combination with ribavirin in 60 treatment-naïve patients with genotype 1 chronic hepatitis C virus (HCV) infection. In the trial, treatment with IMO-2125 in combination with ribavirin was well tolerated and achieved substantial decline in virus levels at two days after the first dose of IMO-2125 and after four weeks of treatment.

20 Dec 2010

Pharmaceuticals News and Research

Jazz Pharmaceutical receives USPTO patent for Xyrem oral solution

Mesa Labs announces acquisition of Apex's biological indicators business

AIDS Healthcare Foundation sues AIDS drug maker for overcharging

Isis commences ISIS-APOCIIIRx Phase 1 trial in hypertriglyceridemia

Pro-Pharmaceuticals, Mount Sinai collaborate to evaluate anti-fibrotic effects of Galectin-targeting compounds

Study aims to deliver safer bone marrow transplant treatment strategy in patients with multiple myeloma cancer

Poniard completes voluntary prepayment of $12.35 million under senior secured loan facility

BioInvent, Japanese pharmaceutical extends partnership for therapeutic candidate development

XFELs technology can track damaged membrane protein structure

Laser restoration therapy promotes hair regrowth in women

Amylin submits metreleptin rolling submission BLA for treatment of rare forms of lipodystrophy

Silence provides year-end update on trading and offer-period

Auspex, Teva Pharmaceutical to develop deuterium-containing drug

New research sheds light on complex regulatory pathways for effective innate immune system

Study: Chemotherapy can improve survival rate in older adolescents with leukemia

Veeva announces seamless integration of CRM solution with Mederi

Brilinta – AstraZeneca’s new blood thinner faces FDA hurdle

Opsens unveils EasyWire for growth market of Fractional Flow Reserve for coronary lesion assessment

Rexahn granted Japanese patent for preclinical compound RX-0047

Idera reports positive data from IMO-2125/ribavirin combination Phase 1 trial in null-responder HCV patients

A guide to density measurement excellence eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence